Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

This study will compare the tolerability of Quetiapine Fumarate immediate release formulation and Quetiapine Fumarate extended release formulation during initial dose escalation in healthy volunteers.

Key facts

Study ID

NCT00702676

Run by

AstraZeneca

People needed

63

Starts

2008-07-01

Expected to finish

2008-08-01

Last updated by the study team

2009-07-16

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Provision of informed consent prior to any study specific procedures
• Weight of at least 50 kg

You may not qualify if…

• A history or presence of neurological, hematological, psychiatric, gastrointestinal, hepatic, pulmonary, or renal disease or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
• Positive test results for alcohol or drugs of abuse
• Positive test results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody

Where it is running

• Research Site — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.